Zang Hee Lee

Zang Hee Lee

Auto-generated profile, based on publicly available information

Zang Hee Lee

Department of Cell and Developmental Biology, Dental Research Institute, School of Dentistry, Seoul National University, Seoul 110-749, Republic of Korea

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2017 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
JLJong-Ho Lee
Jong-Ho Lee
BKBongjun Kim
Bongjun Kim
WJWonJong Jin
WonJong Jin
HKHong-Hee Kim
Hong-Hee Kim
HHHyunil Ha
Hyunil Ha
ZLZang Hee Lee
Zang Hee Lee
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by uncontrolled joint inflammation and destruction of bone and cartilage. We previously reported that C-X-C motif chemokine 10 (CXCL10; also called IP-10) has important roles in joint inflammation and bone destruction in arthritis. However, the specific mechanisms by which CXCL10 regulates the recruitment of inflammatory cells and the production of osteoclastogenic cytokines in RA progression are not fully understood. Bone marrow-derived macrophages and CD4+ T cells were isolated from wild-type (WT), Cxcl10 –/–, and Cxcr3 –/– mice. CXCL10-induced migration was performed using a Boyden chamber, and CXCL10-stimulated production of osteoclastogenic cytokines was measured by quantitative real-time PCR and ELISA. Collagen antibody-induced arthritis (CAIA) was induced by administration of collagen type II antibodies and lipopolysaccharide to the mice. Clinical scores were analyzed and hind paws were collected for high-resolution micro-CT, and histomorphometry. Serum was used to assess bone turnover and levels of osteoclastogenic cytokines. CXCL10 increased the migration of inflammatory cells through C-X-C chemokine receptor 3 (CXCR3)-mediated, but not toll-like receptor 4 (TLR4)-mediated, ERK activation. Interestingly, both receptors CXCR3 and TLR4 were simultaneously required for CXCL10-stimulated production of osteoclastogenic cytokines in CD4+ T cells. Furthermore, calcineurin-dependent NFATc1 activation was essential for CXCL10-induced RANKL expression. In vivo, F4/80+ macrophages and CD4+ T cells robustly infiltrated into synovium of WT mice with CAIA but were significantly reduced in both Cxcl10 –/– and Cxcr3 –/– mice. Serum concentrations of osteoclastogenic cytokines and bone destruction were also reduced in the knockout mice, leading to attenuated progression of arthritis. These findings highlight the importance of CXCL10 signaling in the pathogenesis of RA and provide previously unidentified details of the mechanisms by which CXCL10 promotes the development of arthritis.

1 July 2012 in Cancer Research
Verified
Journal Article
Open access
PDF file
JLJong-Ho Lee
Jong-Ho Lee
HKHa-Neui Kim
Ha-Neui Kim
KKKyung-Ok Kim
Kyung-Ok Kim
WJWonJong Jin
WonJong Jin
SLSeungbok Lee
Seungbok Lee
ZLZang Hee Lee
Zang Hee Lee
Amplification of the chemokines CXCL10 and RANKL has been suggested to promote osteoclast differentiation and osteolytic bone metastasis, but a function for endogenous CXCL10 in these processes is not well established. In this study, we show that endogenous CXCL10 is critical to recruit cancer cells to bone, support osteoclast differentiation and promote for the formation of osteolytic bone metastases. Neutralizing CXCL10 antibody reduced migration of cancer cells expressing the CXCL10 receptor CXCR3, and loss of CXCR3 or CXCL10 decreased bone tumor burden in vivo. Bone colonization augmented host production of CXCL10, which was required for cancer growth and subsequent osteolysis. Direct interactions between cancer cells and macrophages further stimulated CXCL10 production from macrophages. Growth of bone metastases required CXCL10-stimulated adhesion of cancer cells to type I collagen as well as RANKL-mediated osteoclast formation. Together, our findings show that CXCL10 facilitates trafficking of CXCR3-expressing cancer cells to bone, which augments its own production and promotes osteoclastic differentiation. CXCL10 therefore may represent a therapeutic target for osteolytic bone metastasis. Cancer Res; 72(13); 3175–86. ©2012 AACR.

25 April 2008 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
HKHan Bok Kwak
Han Bok Kwak
HHHyunil Ha
Hyunil Ha
HKHa‐Neui Kim
Ha‐Neui Kim
JLJong‐Ho Lee
Jong‐Ho Lee
HKHun Soo Kim
Hun Soo Kim
ZLZang Hee Lee
Zang Hee Lee
Objective: Interferon‐γ–inducible protein 10 (IP‐10; also called CXCL10), a chemokine important in the migration and proliferation of T cells, is induced in a wide variety of cell types. However, the role of IP‐10 in rheumatoid arthritis (RA) remains largely unknown. The purpose of this study was to examine the potential role of IP‐10 in bone resorption and RA through examination of a mouse model of collagen‐induced arthritis (CIA).Methods: The effects of IP‐10 on mouse T cells during osteoclast differentiation were examined in migration assays. The bone‐erosive activity of IP‐10 was determined in vivo in a mouse model of CIA by histologic and immunostaining analyses. Cytokine levels in serum and culture medium were measured with sandwich enzyme‐linked immunosorbent assays.Results: Serum concentrations of IP‐10 were significantly higher in mice with CIA than in control mice. RANKL greatly induced IP‐10 expression in osteoclast precursors, but not in mature osteoclasts. IP‐10 stimulated the expression of RANKL and tumor necrosis factor α (TNFα) in CD4+ T cells and induced osteoclastogenesis in cocultures of CD4+ T cells and osteoclast precursors. However, IP‐10 did not induce RANKL or TNFα in CD8+ T cells. Treatment with neutralizing antibody to IP‐10 significantly inhibited the infiltration of CD4+ T cells and F4/80+ macrophages into the synovium and attenuated bone destruction in mice with CIA. Furthermore, levels of RANKL and TNFα were inhibited by antibody to IP‐10. Bone erosion was observed in mice infected with an IP‐10 retrovirus.Conclusion: Our findings suggest that IP‐10 plays a critical role in the infiltration of CD4+ T cells and F4/80+ macrophages into inflamed joints and causes bone destruction. Our results provide the first evidence that IP‐10 contributes to the recruitment of inflammatory cells and is involved in bone erosion in inflamed joints.

1 May 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JLJong-Ho Lee
Jong-Ho Lee
HKHa-Neui Kim
Ha-Neui Kim
DYDaum Yang
Daum Yang
KJKyoungsuk Jung
Kyoungsuk Jung
HKHyun-Man Kim
Hyun-Man Kim
ZLZang Hee Lee
Zang Hee Lee
Excessive receptor activator of NF-κB ligand (RANKL) signaling causes enhanced osteoclast formation and bone resorption. Thus, down-regulation of RANKL expression or its downstream signals may be a therapeutic approach to the treatment of pathological bone loss. In this study, we investigated the effects of Trolox, a water-soluble vitamin E analogue, on osteoclastogenesis and RANKL signaling. Trolox potently inhibited interleukin-1-induced osteoclast formation in bone marrow cell-osteoblast coculture by abrogating RANKL induction in osteoblasts. This RANKL reduction was attributed to the reduced production of prostaglandin E2 via a down-regulation of cyclooxygenase-2 activity. We also found that Trolox inhibited osteoclast formation from bone marrow macrophages induced by macrophage colony-stimulating factor plus RANKL in a reversible manner. Trolox was effective only when present during the early stage of culture, which implies that it targets early osteoclast precursors. Pretreatment with Trolox did not affect RANKL-induced early signaling pathways, including MAPKs, NF-κB, and Akt. We found that Trolox down-regulated the induction by RANKL of c-Fos protein by suppressing its translation. Ectopic overexpression of c-Fos rescued the inhibition of osteoclastogenesis by Trolox in bone marrow macrophages. Trolox also suppressed interleukin-1-induced osteoclast formation and bone loss in mouse calvarial bone. Taken together, our findings indicate that Trolox prevents osteoclast formation and bone loss by inhibiting both RANKL induction in osteoblasts and c-Fos expression in osteoclast precursors.

17 February 2017 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
WJWonJong Jin
WonJong Jin
BKBongjun Kim
Bongjun Kim
DKDarong Kim
Darong Kim
HCHea-Young Park Choo
Hea-Young Park Choo
HKHong-Hee Kim
Hong-Hee Kim
ZLZang Hee Lee
Zang Hee Lee
The chemokine CXCL10 and its receptor CXCR3 play a role in breast cancer metastasis to bone and osteoclast activation. However, the mechanism of CXCL10/CXCR3-induced intracellular signaling has not been fully investigated. To evaluate CXCL10-induced cellular events in the mouse breast cancer cell line 4T1, we developed a new synthetic CXCR3 antagonist JN-2. In this study, we observed that secretion of CXCL10 in the supernatant of 4T1 cells was gradually increased during cell growth. JN-2 inhibited basal and CXCL10-induced CXCL10 expression and cell motility in 4T1 cells. Treatment of 4T1 cells with CXCL10 increased the expression of P65, a subunit of the NF-κB pathway, via activation of the NF-κB transcriptional activity. Ectopic overexpression of P65 increased CXCL10 secretion and blunted JN-2-induced suppression of CXCL10 secretion, whereas overexpression of IκBα suppressed CXCL10 secretion. These results indicate that the CXCL10/CXCR3 axis creates a positive feedback loop through the canonical NF-κB signaling pathway in 4T1 cells. In addition, treatment of osteoblasts with conditioned medium from JN-2-treated 4T1 cells inhibited the expression of RANKL, a crucial cytokine for osteoclast differentiation, which resulted in an inhibitory effect on osteoclast differentiation in the co-culture system of bone marrow-derived macrophages and osteoblasts. Direct intrafemoral injection of 4T1 cells induced severe bone destruction; however, this effect was suppressed by the CXCR3 antagonist via downregulation of P65 expression in an animal model. Collectively, these results suggest that the CXCL10/CXCR3-mediated NF-κB signaling pathway plays a role in the control of autonomous regulation of CXCL10 and malignant tumor properties in breast cancer 4T1 cells.

1 February 2008 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
HHHyunil Ha
Hyunil Ha
JLJong-Ho Lee
Jong-Ho Lee
HKHa-Neui Kim
Ha-Neui Kim
HKHan Bok Kwak
Han Bok Kwak
HKHyun-Man Kim
Hyun-Man Kim
ZLZang Hee Lee
Zang Hee Lee
Osteoclasts are bone-resorbing cells that are differentiated from hemopoietic precursors of the monocyte-macrophage lineage. Stimulation of TLRs has been shown to positively or negatively modulate osteoclast differentiation, depending on the experimental condition. However, the molecular mechanism by which this modulation takes place remains unclear. In the present study, we examined the effects of flagellin, a specific microbial ligand of TLR5, on the receptor activator of NF-κB ligand (RANKL)-stimulated osteoclastogenesis. Flagellin suppressed RANKL induction of c-Fos protein expression in bone marrow-derived macrophages without affecting c-Fos mRNA expression. Ectopic overexpression of c-Fos and a constitutively active form of NFATc1 reversed the flagellin-induced anti-osteoclastogenic effect. The inhibitory effect of flagellin was mediated by IFN-β production. Flagellin stimulated IFN-β expression and release in bone marrow-derived macrophages, and IFN-β-neutralizing Ab prevented the flagellin-induced c-Fos down-regulation and the anti-osteoclastogenic effect. IFN-β gene induction by flagellin, LPS, or RANKL was dependent on STAT1 activation. Treatment with flagellin or RANKL stimulated STAT1 activation, and STAT1 deficiency or the JAK2 inhibitor AG490 dramatically prevented IFN-β induction in response to flagellin or RANKL. In addition, STAT1 deficiency abolished the anti-osteoclastogenic effect induced by flagellin or LPS. In contrast, flagellin stimulated osteoclast differentiation in cocultures of osteoblasts and bone marrow cells without inducing IFN-β. Thus, IFN-β acts as a critical modulator of osteoclastogenesis in response to TLR5 activation.